|
||||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
| UDK 616.42-006.44 |
ISSN 035-2899, 37(2012) No 2 p.65-73 |
|||||||||||||||||||||||||||||||||||
|
Original paper Prognostic Factors in Patients with Diffuse Large B-cell Lymphoma (Prognostički činioci kod obolelih od difuznog krupnoćelijskog B-limfoma) Snežana Sretenović (1), Biljana Mihaljević (2), Nebojša Anđelković (1), Boško Anđelić (2), Ljuba Jaković (2), Snežana Janković (2), Ružica Jančić-Nedeljkov (2) (1) KLINIČKI CENTAR KRAGUJEVAC, CENTAR ZA HEMATOLOGIJU, KRAGUJEVAC, (2) KLINIČKI CENTAR SRBIJE, KLINIKA ZA HEMATOLOGIJU, BEOGRAD |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| Summary: INTRODUCTION: Diffuse large B-cell lymphoma /DBCL/ is a diffuse proliferation of large neoplastic B-lymphocytes, which is very heterogeneous, both in the clinical and the genetic and molecular levels. OBJECTIVES: 1) to compare the overall treatment response and overall survival (OS) in our patients with respect to sex, age and B symptoms, 2) to assess the impact of lactate dehydrogenase /LDH/ serum level, hemoglobin /Hb/ concentration and sedimentation rate at diagnosis on OS of our patients, 3) to determine and define the overall therapeutic response, i.e. survival of DBCL patients depending on the clinical stage /CS/ according to Ann Arbor classification. MATERIAL AND METHODS: this is a retrospective study performed between January 2000 and October 2006. The data were collected from written medical records of the Institute of Hematology, the Clinical Centre of Serbia, Belgrade. The study included 119 patients with nodal and extranodal localization of non-Hodgkin lymphoma (NHL), DBCL type. The methods of analytical statistics were used for data processing: Hi2 – and Mann-Whitney U test /Rank sum test/. The survival analysis was performed by Kaplan-Meier method; Long- Rank test compared the OS between the two groups. p<0.05 was considered as statistically significant. RESULTS: There was no relationship between the patients' sex and age (<and≥60 years) on the one hand and OS on the other (p=0,779 and p=0,226, respectively). Besides, the patients with B symptoms exhibited worse OS as compared to the patients with A symptoms (Long-Rank test, p=0.0008). Moreover, hemoglobin level did not have an impact on OS (Long-Rank test, p=0,108); conversely, the LDH level significantly affected the patients' outcome (Long-Rank test, p=0.0437). The patients with the advanced disease (CS IIICS IV) had a significantly worse OS (Long Rank test; p=0.0002) as compared to the patients with NHL, DBKL, CS I and CS II. The patients in earlier clinical stage lived longer than those in later clinical stage. CONCLUSION: This is the first analysis of prognostic factors and overall survival in DBCL patients in our country. Our results are in line with reports from other countries. Key words: diffuse large B-cell lymphoma, prognostic factors, overall survival Napomena: kompletan tekst rada na srpskom jeziku Note: full text in Serbian |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
Corresponding Address: Snežana Sretenović Moravska br. 8/2, 34 000 Kragujevac e-mail : sretenovicsnezana@yahoo.com |
Paper received: 29.3.2012 Paper accepted: 23.9.2012 Paper Internet issues: 12.11.2012 |
|||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
